You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

AZ/Daiichi Sankyo’s antibody drug conjugates prove promising in early

AstraZeneca (AZ) and Daiichi Sankyo have posted new data from Phase I/II trials evaluating their respective antibody drug conjugates (ADCs) Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan.